The effect of prolonged time for achieving ovarian suppression before starting stimulation on pregnancy rates in ART cycles by Yoldemir, Tevfik
ORIGINAL ARTICLE/ÖZGÜN ARAŞTIRMA
77
Introduction
Controlled ovarian stimulation in assisted reproductive 
technologies (ART) induces multiple follicular recruitment 
and allows the harvesting of multiple oocytes to obtain 
embryos. During initial studies with human menopausal 
gonadotropin (HMG) stimulation of multiple follicle 
development for in vitro fertilizing (IVF), a premature 
luteinizing hormone  (LH)  peak occurred in around 20–25% 
of  the cycles. This advanced exposure to high LH resulted 
in the premature luteinization of follicles and  the  induction 
of oocyte maturation, resulting in either cycle cancellation or 
compromised IVF outcome. The most widely used protocol 
for ovarian stimulation in ART cycles is the long down-
regulation protocol, for which gonadotropins are administered 
after pituitary suppression with  gonadotropin- releasing 
hormone (GnRH) agonists. With the clinical development of 
GnRH agonists in the early 1980s, there was not only  the 
increase  in pregnancy and live-birth rates, but also a more 
flexible timing for oocyte retrieval became  possible in IVF 
treatments [1].
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ABSTRACT 
Objective: To determine if the prolonged time for  achieving 
ovarian suppression before starting  stimulation affected  the 
pregnancy rates.
Patients and Methods: Retrospective cohort analysis was 
performed on 565 women undergoing first assisted reproductive 
technologies (ART) treatment in a University-affiliated Hospital. 
The women were grouped according to the duration of down-
regulation by gonadotropin-releasing hormone (GnRH)  analogue. 
Group A consisted of women in the lower 25th percentile, group 
B consisted of women in the upper 25th percentile,  according to 
the duration of GnRH analogue use. The implantation and clinical 
pregnancy rates were compared. 
Results: Mean number of aspirated and inseminated oocytes 
were more in group A than in group B.  Implantation rates were 
similar. Clinical pregnancy rates were alike. 
Conclusion: Prolonged time for achieving  ovarian supression 
does not compromise clinical pregnancy rates in ART cycles.
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ÖZET
Amaç: Stimulasyona başlamadan önce ovaryen süpresyonun 
uzamasının gebelik oranlarına etkisini araştırmak 
Hastalar ve Yöntem: Üniversite affiliye hastanede yardımcı 
üreme tetkikleri (assisted reproductive technologies (ART)) 
tedavileri yapılan 565 hasta retrospektif olarak incelendi. Kadınlar 
gonadotropin salgılayan hormon (gonadotropin releasing hormone 
(GnRH)) analogu ile ovaryen süpresyon süresine göre gruplandırıldı. 
GnRH analog kullanım süresine göre grup A alt 25 persentil içinde, 
grup B de üst 25 persentil içindeki hastalardan oluşmaktaydı. 
İmplantasyon ve klinik gebelik oranları karşılaştırıldı. 
Bulgular: Grup A’da ortalama aspire edilen ve insemine edilen 
oosit sayısı grup B’dekinden fazla idi. İmplantasyon oranları benzer 
idi. Klinik gebelik oranları benzer idi. 
Sonuçlar: Ovaryen süpresyon için geçen zamanın uzaması 
ART sikluslarında klinik gebelik oranlarını olumsuz etkilemez.
Anahtar kelimeler: GnRH, ART, Ovaryen süpresyon, Gebelik, 
Uzun protokol
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Duration of down-regulation and ART pregnancy
Because of the intrinsic agonist activity of the GnRH 
agonists, pituitary down-regulation is preceded by an initial 
stimulatory phase, which lasts for two weeks. The  timing 
of ovarian quiescence after this initial stimulation phase is 
highly variable. This flare effect renders the GnRH agonist 
‘long-protocol’ approach more time consuming, because 
ovarian stimulation can only begin when pituitary quiescence 
has occurred.  Long-acting forms of GnRH analogues  were 
studied in IVF cycles and no difference in cycle outcome 
was demonstrated [2,3]. Scott et al. [4] did not observe any 
impact of the duration of GnRH analogue use on ovarian 
responsiveness to gonadotrophins, nor on IVF success after 
using leuprolide for 14–15 days prior to ovulation induction. 
They found no reason to start stimulating patients as soon as 
suppression was achieved. Moreover,  higher implantation 
rates in amenorrhoeic patients have been reported [5].
It is uncertain whether the ovarian response to exogenous 
stimulation is affected by GnRH agonist co-treatment [6]. 
We aimed to determine whether the prolonged  time for 
achieving  ovarian suppression before starting  stimulation 
affected   the pregnancy rates in IVF/intracytoplasmic sperm 
injection (ICSI) cycles.  
Patients and Methods
Five  hundred and sixty five consecutive women undergoing 
ART cycles in a University- affiliated Hospital, were selected 
for retrospective evaluation. The women were placed in two 
groups according to the duration of GnRH analogue use. The 
mean length of the GnRH analogue use among these women 
was 27.62± 3.27 days. Group A consisted of women who used 
GnRH analogue for a duration in the lower 25th percentile, 
group  B consisted of women who used GnRH analogue for 
a duration  in the upper 25th percentile.  The period of GnRH 
analogue was calculated from the time of start on day 21 of 
the preceeding cycle till the the day of  the human chorionic 
gonadotrophin (hCG)  injection. Ethical approval for the 
study was not required and has not been included as there 
were no interventions that are not a part of standard care. All 
practices and protocols conformed to the ethical requirements 
for assisted reproductive technology programs of the Ethics 
Commitee of the institution and  conform to the provisions of 
the Declaration of Helsinki. 
Hormonal stimulation 
All patients underwent ovarian stimulation with 
gonadotropins and gonadotropin releasing-hormone (GnRH)-
agonist for pituitary down-regulation. For long protocols, 
pituitary desensitization was achieved by s.c. administration 
of leuprolide acetate (Lupron; TAP Pharmaceuticals, North 
Chicago, IL) during the luteal phase of the preceding 
cycle before the start of gonadotropin stimulation. After 
down-regulation was confirmed by E2 levels <50 pg/ml, 
controlled ovarian hyperstimulation was accomplished 
with s.c. administration of recombinant follicle-stimulating 
hormone (FSH) (Follitropin alpha; Serono Inc).  None of 
the patients had E2 >50 pg/ml before ovarian stimulation 
was started.  Gonadotropins were initiated the day after the 
baseline evaluation, or several days later,  as required,  based 
on the  desired retrieval day. The agonists  were sometimes 
continued longer in order to avoid weekend retrievals. 
Follicular monitoring was performed by using a Toshiba 
SAL 77B machine (Toshiba, Tokyo, Japan). Ten thousand IU 
of human chorionic gonadotropin (hCG, 10,000 IU Profasi, 
EMD Serono Inc.) was administered when at least one 
follicle had a mean diameter of 18 mm. 
Oocyte retrieval, insemination, embryo culture, and 
grading transvaginal oocyte retrieval was performed 35 or 36 
hours after hCG injection. The decision to perform standard 
IVF, ICSI was based on a diagnosis of infertility.  For 
cleavage-stage embryo transfer, embryos were cultured in 
P1 medium (Irvine Scientific, Santa Ana, CA). The Women 
and Infants Hospital (WIH) Scoring system was used 
on a selection of day 3 embryos (Table I). The individual 
WIH score of each embryo was calculated as the sum of 
“development+ fragmentation+symmetry”. The average 
embryo score was recorded for each day 3 embryo transfer. 
Cleavage-stage embryo transfers were performed by using a 
Wallace (Cooper Surgical, Shelton, CT) or Embryon catheter 
(Sage BioPharma, Bedminster, NJ). 
Embryo transfer was performed with transabdominal 
ultrasonographic guidance using a Toshiba SAL 77B machine 
(Toshiba, Tokyo, Japan). 
Biochemical pregnancy was determined by serum hCG 
levels measured 12 days after the embryo transfer. Clinical 
pregnancy was determined by the presence of a gestational 
sac during an ultrasound exam. The implantation rate was 
calculated as the ratio between the number of embryonal 
sacs diagnosed by sonography and the total number of 
embryos transferred into the uterus. Clinical pregnancy rates 
and implantation rates were calculated per embryo transfer. 
Luteal support consisted of the  daily use of transvaginal 
progesterone gel (Crinone 8%; Serono Inc.) through the 10 
weeks of gestation. 
Table I. Women and Infants Hospital (WIH) scoring for day 3 embryos
Cell number Score
Degree of 
fragmentation Score Symmetry Score
8-10 4 0 4
Symmetric 
or slightly 
asymmetric
1
6-7 or >10 3 <10% 3 Grossly 
asymmetric
0
4-5 2 10-25% 2
2-3 1 26-50% 1
1 0
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Statistical Evaluation
All analyses used StataSE 10.0 computer software 
(Statacorp, Texas).  Student’s t-test was used  for the 
whole group statistical evaluation ; p<0.05 was considered 
significant. 
Results
There were 163 women in group A and 146 in group B. The 
mean age , serum level of FSH on cycle day 3 and body mass 
index (BMI) were similar between the groups. Diagnosis 
for infertility in group A were male factor (28.3%), tubal 
(17.1%), minimal endometriosis (10.5%), polycyctic ovary 
syndrome (PCOS) (6.6%) or unexplained infertility (27%). 
The percentages of distribution in group B were 28.3%, 
21%, 5.8%, 5.8% and 28.3%, respectively. The mean serum 
estradiol level on the day of the hCG injection was similar. 
The ovarian suppression length before the commencement 
of gonadotropins was longer in group B than in group A 
(22.38± 2.42 vs 15.33± 1.26, p=0.0001). The duration of 
gonadotropin stimulation, and the total dose of gonadotropins 
were higher in group B. The mean number of eggs collected, 
the mean number of mature oocytes were more in group B 
than in group A. However the number of fertilized oocytes 
were similar (Table II).  
On day 3, the mean number of embryos with more than 6 
cells were similar between the groups.  Likewise,  the average 
embryo scores of transfered embryos were comparable 
between the groups (Table III). The mean number of embryos 
transferred were similar between groups (3.25± 0.91 vs 3.38± 
0.83; p=0.27). The implantation  rate and clinical pregnancy 
rate per cleavage stage transfers was alike between the groups 
(Table III). 
Discussion 
Because of the intrinsic agonist activity of the GnRH 
agonists, pituitary down-regulation is preceded by an initial 
stimulatory phase which lasts for two weeks. A progressive 
decrease in LH β subunits within the 7 days of the agonist 
administration, regardless of the duration of GnRH agonist 
administration is observed. By contrast, LH α subunit 
secretion seemed to be dependent on the duration of the 
treatment [7]. Unlike LH [8], FSH bioactivity does not 
decrease during GnRH agonist administration [9]. Plasma 
FSH concentrations are not influenced by the duration of the 
treatment. It may therefore be speculated that the apparent 
beneficial effect of maintaining GnRH agonist administration 
for 14 days is related to the persistence of  bio-FSH secretion. 
With a progressive decrease in plasma LH concentrations, a 
second inhibition phase is observed. During this period and 
as long as GnRHa administration is maintained, the pituitary 
seems completely refractory to GnRH action [10]. The 
intensity and duration of hypophyseal desensitization for LH 
are dose dependent [11]. After  21 days of desensitization, 
LH bioactivity is completely suppressed [9]. 
Table II. The demographics of the study groups
Groups  (n) Group A (n=163) Group B (n=146) P value
Mean age (years) 33.69± 4.77 34.34± 4.38 0.22
Cycle day 3 FSH (mIU/ml) 5.85± 2.17 6.25± 2.34 0.12
Body mass index (kg/m2) 27.84± 8.15 26.22± 7.62 0.12
Duration of GnRH analogue use (days) 24.06± 0.98 32.14± 1.89 0.0001
Ovarian suppression before gonadotropin start (days) 15.33± 1.26 22.38± 2.42 0.0001
Duration of  stimulation with gonadotropin (days) 8.72± 1.16 9.75± 1.85 0.0001
Gonadotropin start dose (IU) 294.48± 103.60 317.47± 110.73 0.06
Total gonadotropin dose (IU) 2437.27± 1000.01 3024.83± 1344.34 0.0001
E2 level on HCG day (pg/ml) 1853.64± 955.55 1697.66± 854.03 0.14
Number of aspirated oocytes per retrieval 14.27± 8.47 11.93± 6.17 0.01
Number of inseminated oocytes per retrieval 13.10± 8.30 10.99± 6.04 0.02
Number of fertilized oocytes per retrieval 8.82± 6.82 7.56± 5.29 0.15
Number of embryos with >6 cells by day 3 4.84± 4.97 4.22± 3.74 0.29
All values are shown as mean ± standard deviation (# mean ± SD) ; p< 0.05 is statistically significant
Table III. Pregnancy outcome in groups
Group A
(n=163)
Group B
(n=146)
P value
Average score of transferred 
embryos on day 3 *
6.51±1.34 6.46±1.20 0.78
Number of embryos
transfered on day 3
3.25± 0.91 3.38± 0.83 0.27
Implantation rate per transfer (%) 21.90± 0.30 20.79± 0.29 0.77
Biochemical pregnancy rate per 
cleavage stage transfer (%)
47.26±0.50 54.48±0.50 0.23
Clinical pregnancy per cleavage 
stage transfer (%)
41.78±0.49 45.19±0.50 0.56
Mean ± standard deviation.
P < 0.05 is considered as statistically insignificant 
* WIH Score = development+ fragmentation+symmetry
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The present study investigated whether the duration of 
ovarian suppression by GnRH agonist affects pregnancy 
rates in long-down regulated IVF/ICSI cycles. ART cycles 
pre-treated with GnRH agonists have resulted in superior 
pregnancy rates when compared with cycles not utilizing 
analogues [12- 14]. There was not only  an increase in the 
number of developing follicles  [15, 16], but also premature 
luteinizing hormone (LH) surges were prevented [17, 18]. 
A long protocol of down-regulation allows for the complete 
suppression of estradiol before ovarian stimulation is begun. 
This suppression process may take at least 14 days [19, 20]. 
Tarlatzis et al. [21] and Tan et al. [22] have shown higher 
implantation and pregnancy rates using  the long protocol. This 
has been attributed to more effective LH suppression, higher 
oocyte retrieval per cycle and  more  developed embryos. 
In our study, although higher doses of gonadotropins were 
used in group B than in group A, more oocytes were retrieved 
and inseminated  in group A. However,  mean number of 
fertilized oocytes were comparable in both groups. Similarly, 
the average embryo score of transferred embryos  and the 
number of transferred embryos on day 3 were comparable. 
Similar clinical pregnancy rates were detected  in both 
groups. 
A comparison of implantation rates between different 
protocols has led us to believe that the beneficial effects of 
GnRH agonists were related to an improved endometrial 
receptivity [23]. However, a direct action of GnRH agonist 
on the endometrium remains speculative. In our study,  the 
implantation rates between the groups were compatible. Since 
LH/hCG receptors have been recognized at the endometrial 
level [24, 25], another way for GnRH analogue to influence 
uterine receptivity might be through the reduction of 
gonadotrophin synthesis, with subsequent consequences on 
endometrial LH receptor function. In our study,  even though 
a higher total dose of FSH was used per cycle in group B, the 
mean serum estradiol level on the day of the  hCG was similar 
between the groups and thus the effect of rising estradiol 
levels on the endometrium was comparable. Hence,  the 
prolonged use of  GnRH analogue  did not influence uterine 
receptivity,  as shown by the similar implantation rates.
Patients with hypogonadotropic hypogonadism showed a 
significantly higher pregnancy rate after ovarian stimulation 
using exogenous gonadotropins, than in normogonadotropic 
women [26]. Even though a significantly higher rate 
of implantation has been reported, the reasons for this 
enhanced fertility in amenorrhoeic women are still partially 
unknown. Our findings could not support this increased 
rate of implantation. With comparable numbers of embryos 
transferred in both groups, clinical pregnancy rates were 
similar between the groups. 
Conclusion
It appears that prolonged GnRH analogue use does not 
compromise IVF/ICSI results. Hence,  IVF laboratory 
schedules might be adjusted for normo-responders in order to 
omit weekend egg retrievals and embryo transfers. However, 
prospective cohort studies are necessary to support our 
results.
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